INTRODUCTION
In obesity hypoventilation syndrome (OHS), chronic hypercapnia develops as a consequence of obesity. This condition is associated with alveolar hypoventilation, restricted pulmonary function, severe sleep-disordered breathing and higher rates of morbidity, mortality and healthcare costs compared with eucapnic obesity. [1] [2] [3] [4] OHS affects approximately 0.15-0.3% of the US population 5 and over 50% of hospital inpatients with body mass index (BMI)>50 kg/m 2 . 1 Despite this, OHS frequently goes undiagnosed among hospital inpatients with obesity. 1 Supplemental oxygen is a common medical intervention 6 and may be administered to patients with OHS in a range of healthcare settings. British Thoracic Society guidelines on emergency oxygen prescription identify patients with OHS as a group among whom excessive concentrations of supplemental oxygen, causing hyperoxia, could increase carbon dioxide (CO 2 ) levels and lower pH. 6 The basis of the guidelines relies upon expert opinion and data from COPD, because very few studies have investigated the effects of supplemental oxygen in OHS. Among patients with obesity and elevated transcutaneous CO 2 pressure (PCO 2 ), breathing 100% oxygen induced an average rise in transcutaneous PCO 2 of 0.7 kPa (with rises of >1.3 kPa in three patients). 7 However, the effect of oxygen on pH, an important prognostic indicator, 2 8 9 was not reported. Furthermore, 100% oxygen is rarely used in clinical practice. 7 Hence, the clinical relevance of these data is uncertain.
During acute exacerbations of COPD, hyperoxia arising from supplemental oxygen worsens hypercapnia and pH, and has been linked to more frequent admission to intensive care and increased hospital length of stay and mortality. [9] [10] [11] Hyperoxia-induced hypercapnia in COPD has been attributed to increased ventilation/perfusion (V/Q) inequality, mediated by the reversal of hypoxic vasoconstriction [12] [13] [14] ; however recent evidence suggests that hypoventilation may be a quantitatively more important mechanism. 15 16 Whether or not these mechanisms apply to OHS, which has a vastly different pathophysiology to COPD, has yet to be determined.
The aims of the present study were to document the time course of changes in PCO 2 , pH and respiratory variables in response to clinically relevant, moderate concentrations of supplemental oxygen among people with OHS in comparison to a healthy control group; and to examine physiological mechanisms that may explain any oxygen-induced changes in PCO 2 . 
METHODS

Participants
Patients referred to the Sleep Unit, Royal Prince Alfred Hospital with obesity and possible hypercapnia were screened for eligibility. Inclusion criteria were the combination of obesity (BMI ≥ 30 kg/m 2 ) and daytime hypercapnia (arterial PCO 2 (PaCO 2 ) > 6 kPa) . Patients were excluded in the case of any other potential cause of hypercapnia, current use of positive airway pressure, acute respiratory/cardiac illness within the previous month, acidaemia or psychiatric illness. A control group was recruited concurrently from a sample of convenience. Each control participant was age (±3 years) and gender matched with an OHS participant, non-smoking, with BMI < 30 kg/m 2 , normal spirometry and no history of cardiorespiratory disease.
Study design and protocol
Using a double-blind randomised crossover design (figure 1), each participant breathed two fractions of inspired oxygen (F i O 2 ) 0.28 and 0.50 in random order (sequence 1 or 2), via a breathing circuit, after a circuit acclimatisation period. Each test began with a 10 min period of breathing room air via the circuit (baseline), followed by a 20 min period of supplemental oxygen (F i O 2 0.28 or 0.50), and then a 10 min period of breathing room air (recovery). A 45 min washout period separated the two supplemental oxygen tests.
Randomisation of sequence was generated using an online randomisation programme (http://www.randomization.com), with allocation concealed via sealed opaque envelopes. The chief investigator and participants remained blinded throughout. An unblinded coinvestigator operated equipment and instructed participants. Testing began between 8:30am and 10:00am. All participants had fasted and abstained from caffeine from midnight.
Instrumentation
The closed breathing circuit comprised a dry rolling-seal spirometer, a bias-flow generator, a soda-lime CO 2 absorber and a T-connector at the participant interface. Gas was continuously sampled at the interface using oxygen/CO 2 sensors. A stable F i O 2 was maintained through titration of bottled air and oxygen using continuous real-time feedback from the oxygen sensor. Immediately after each F i O 2 change, the circuit was flushed to allow stabilisation at the new F i O 2 within 2 min. Participants breathed through the circuit via a nasal mask (dead space 175 mL) with the mouth closed (n=25), or in the case of nasal obstruction, via a mouthpiece (dead space 100 mL) with a nose peg (n=3).
Outcome measures
On the day of testing, baseline measures of height, weight, spirometry and arterial blood gases (ABGs) were performed.
Arterialised-venous blood was repeatedly sampled to obtain surrogate measures of arterial PCO 2 (PavCO 2 ) and pH. We previously described and validated this method in OHS. 17 An oximeter continuously measured pulse oxygen saturation (SpO 2 ) (Radical, Masimo, Irvine, California, USA). Signals from the oxygen/CO 2 sensors and spirometer were recorded by a computer programme and used to derive and/or display breath-by-breath minute ventilation (V E ), tidal volume (V T ) and respiratory rate (RR). Breath-by-breath physiological dead space (V D phys) was calculated using a CO 2 expirogram method 18 and adjusted by subtracting apparatus dead space, then divided by V T to obtain V D phys to V T ratio (V D /V T ). Data affected by leak or artefact were systematically excluded. Subsequently, breath-by-breath data were averaged over 60 s.
For final analysis, data obtained during the following periods were included: the final minute of the 10 min baseline, the final minute of each 5 min epoch of supplemental oxygen, and the final minute of the 10 min recovery. Arterialised-venous blood samples were drawn within the last 10 s of each of these periods.
Statistical analysis
Data are presented as mean±SD or median (IQR), and mean difference (MD) and 95% CI for between-group comparisons. A significance level of p<0.05 was used for all comparisons. Between-group MDs in baseline variables were compared using Figure 1 Study design. F i O 2 , inspired oxygen fraction. independent t-tests. General linear model (univariate, repeated measures) analysis compared responses to supplemental oxygen between participant groups (factor: group; factor interaction: time-by-group) for primary (PavCO 2 ) and secondary ( pH, V E and V D /V T ) outcomes; between baseline and supplemental oxygen (factor: time) for primary, secondary and tertiary (V T , RR, V D Phys) outcomes; and between the two oxygen concentrations (factor: concentration) for PavCO 2 . For non-parametric data, the Friedman test was used to evaluate effects of time. To account for multiple comparisons the level of significance was adjusted (adj.p) using Holm's Bonferroni procedure. 19 Within the OHS group only, Pearson's correlation coefficient was calculated to examine potential factors associated with the change in (table 1) show that groups were well matched for age and gender. Participants with OHS presented with superobesity, mild hypercapnia and hypoxaemia, and mild pulmonary restriction. Table 2 shows all variables at baseline and after 20 min of breathing each oxygen concentration. In both groups, supplemental oxygen induced hyperoxia, with SpO 2 in OHS increasing to 99±1% during F i O 2 0.28 and 100±0% during F i O 2 0.50. 
Between-group comparisons
Responses to supplemental oxygen were significantly different between groups for PavCO 2 and pH (figure 3, table 3), but not for V E after adjustment. There were no significant between-group differences or interaction effects for V D /V T , hence data from both groups were combined to analyse the effects of time for V D /V T .
OHS group: responses to supplemental oxygen
Amongst OHS participants, significant increases in PavCO 2 occurred after 20 min of F i O 2 0.28 (0.3±0.2 kPa, adj.p=0.013) and F i O 2 0.50 (0.5±0.4 kPa, adj.p=0.012) (table 2, figure 3) . Consequently, proportional changes in pH were observed, resulting in acidaemia after 20 min of F i O 2 0.50 (7.346±0.030, adj. p=0.011). There was a significant difference in PavCO 2 between the two oxygen concentrations, but this became nonsignificant after adjustment (raw p=0.021, adj.p=0.315). figure 3 ). Thereafter, a varying recovery in V E was observed ( figure 4C ), such that after 20 min V E remained below baseline in six participants, returned to baseline in four participants and exceeded baseline V E by >5% in four participants. After 20 min, group mean V E was 3±20% below baseline, which became non-significant after adjustment (raw p=0.014, adj.p=0.224). Decreases in V E were attributable to significant falls in V T , as RR was unchanged. 
Control group: responses to supplemental oxygen
Among the controls, there were no significant changes in PavCO 2 or pH during either F i O 2 (table 2, figure 3) , and no significant differences for PavCO 2 between concentrations. During F i O 2 0.28 there were no significant changes in V E , V T or RR. However, breathing F i O 2 0.50 increased V E by 15±11% after 20 min (adj.p=0.019), due to a slight, non-significant increase in RR (raw p=0.01, adj.p=0.170).
Significant increases in V D /V T of 1±3% and 4±3% were observed during F i O 2 0.28 and 0.50 respectively (adj.p=0.012). This was accompanied by small rises in V D phys which became non-significant after adjustment (raw p<0.001, adj.p=0.085). Among participants with OHS, hyperoxia induced by supplemental oxygen significantly worsened hypercapnia and lowered pH. In an earlier study, breathing 100% oxygen increased transcutaneous PCO 2 in obesity-associated hypercapnia, 7 but the clinical relevance of this report was unclear because pH was not measured and transcutaneous PCO 2 was used, inherently adding potential errors to PCO 2 measures and preventing a definitive diagnosis of OHS. 5 The present study provided further physiological detail and insight into the clinical relevance of the effects of hyperoxia in OHS. Although the minimal important difference for PCO 2 in OHS has not been defined, in the present study the rise in PavCO 2 during F i O 2 0.50 (0.5±04 kPa) was considered clinically significant because it induced acidaemia. In patients with COPD, hyperoxia-related acidaemia is associated with higher in-hospital morbidity, 9 and this may apply to acutely unwell patients with OHS 2 8 but has not been addressed. Therefore, in light of the results of the present study, the influence of supplemental oxygen usage on morbidity, mortality and healthcare utilisation in people with OHS requires investigation.
Ventilatory responses to hyperoxia Controls
Interestingly, V D /V T increased among the control group with both oxygen concentrations, with rises of the same magnitude as those of the OHS group (figure 3). Despite this, PavCO 2 and pH remained relatively stable, albeit with some individual variation (figure 4B). During F i O 2 0.50, stable PavCO 2 levels were achieved by a 15±11% increase in V E . This is consistent with previous observations among healthy controls breathing 100% O 2 20-23 and is indicative of normal ventilatory control. Hyperoxic hyperventilation in healthy individuals is usually preceded by a fall in V E (∼5-12%) within the first 30 s to 2 min of breathing 100% oxygen via inhibition of the peripheral chemoreceptors, which are tonically active within a normal PaO 2 range. 20 21 23 However, the washout time of circuit gases prevented this being captured in the present study. Quickly thereafter, V E increases above baseline due to transient increases in PaCO 2 from initial hypoventilation, 22 23 the Haldane effect, 22 increases in V D /V T and possibly in part through direct stimulation of chemoreceptors.
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Participants with OHS also experienced increases in V D /V T during hyperoxia. However, unlike the controls, breathing F i O 2 0.50 was invariably characterised by marked hypoventilation for the first 5-10 min, followed by a partial recovery in V E . The recovery of V E was usually insufficient to overcome the increase in V D /V T , hence PavCO 2 was elevated after 20 min of F i O 2 0.50 in most participants ( figure 4 ). There was a negative correlation between ΔV E and ΔPavCO 2 , but ΔV D /V T was not associated with ΔPavCO 2 . These results suggest that the PavCO 2 rises observed amongst OHS participants were largely a result of inadequate ventilatory control. Impaired respiratory chemosensitivity is a common feature of OHS [24] [25] [26] and may explain why the initial decrease in V E during hyperoxia was of a larger magnitude, with much slower recovery, than that reported in controls. 21 23 Blunted hypercapnic ventilatory responses could also explain why an elevation of PavCO 2 at 20 min was tolerated by most participants. However, hypercapnic ventilatory responses are highly variable between individuals with OHS and are sometimes within the normal range in patients with mild hypercapnia, [24] [25] [26] which may explain the variability in ventilatory responses to hyperoxia in the OHS group. We did not test ventilatory responses and are therefore unable to confirm their role in the changes in PavCO 2 observed during hyperoxia.
Factors potentially influencing V D /V T in controls and OHS
In both groups, V D /V T increased significantly during hyperoxia, although the contribution of this small change towards potential PavCO 2 rises is uncertain. Increased V D /V T could arise from an increase in V D phys, a decrease in V T or both. In studies measuring V/Q distributions in healthy controls, 27 and patients with OHS, 28 breathing 100% oxygen has been shown to increase perfusion to poorly ventilated regions of lung through the release of local hypoxic vascoconstriction. 27 This results in underperfusion of well ventilated regions, thereby increasing V D phys. 27 This mechanism is plausible among the control group, in whom a small increase in V D phys was observed during F i O 2 0.50. However, this change became non-significant after statistical adjustment. In contrast, no change was observed in V D phys among the OHS group. It has been shown that V D phys has a proportional relationship with V T. 29 30 Therefore in OHS participants, increases in V D phys occurring due to increased V/ Q inequality may have been offset by the concomitant fall in V T . Given the lack of increase in V D phys during hyperoxia among OHS participants, rises in V D /V T are largely attributable to the reduction in V E (via the reduction in V T ), which is consistent with previous observations in patients with obesity-associated hypercapnia whilst breathing 100% oxygen. 7 However, we did not perform invasive V/Q measures and therefore were unable to characterise the complex interactions between pulmonary ventilation and perfusion, gas exchange and breathing pattern when patients were breathing moderate oxygen concentrations.
Clinical implications
Clinically important differences between the two concentrations of oxygen were observed in the present study, that is, hyperoxia induced by F i O 2 0.28 caused minimal changes in pH or V E , while F i O 2 0.50 caused hypoventilation and acidaemia. Furthermore, compared with responses to F i O 2 0.50 in our OHS participants, even more marked changes in PCO 2 and V E occurred during 100% oxygen in obesity-associated hypercapnia. 7 The mechanisms by which hyperoxia induces hypoventilation in OHS remain unclear. However, these findings suggest that a greater degree of respiratory depression occurs with higher oxygen concentrations. Therefore, in stable OHS, hyperoxia caused by breathing F i O 2 0.28 may be less harmful than F i O 2 0.50 or 1.0.
Substantial inter-individual variability in ΔPavCO 2 during hyperoxia was evident among the OHS group; as has been reported in obesity-associated hypercapnia 7 and COPD. 16 Therefore it would be clinically useful to identify features that may predict adverse responses to hyperoxia. Strong associations between ΔPavCO 2 and baseline PaCO 2 and HCO 3 − were observed, suggesting that patients with OHS and severe hypercapnia (and associated elevated HCO 3 − levels) are more likely to develop worsening hypercapnia during hyperoxia. This is plausible, given the tendency for people with OHS and a higher PaCO 2 to have lower hypercapnic ventilatory responses than those with lower PaCO 2 . [24] [25] [26] Elevated HCO 3 − may also directly blunt hypercapnic ventilatory responses in OHS, through an increased acid-buffering capacity. 31 32 Previous data also suggest that people with more severe hypoxaemia may experience larger PCO 2 rises during hyperoxia, 7 although this was not evident amongst our mildly hypoxaemic group.
Participants in the present study were clinically stable, with mild hypercapnia and hypoxaemia. Therefore our findings probably underestimate the dangers of hyperoxia in people with OHS with severe hypercapnia and/or acute cardiorespiratory illness. The effects of supplemental oxygen in this population warrant further investigation. Even so, the findings of the present study highlight the potential risks associated with the administration of moderate concentrations of supplemental oxygen among people with OHS. These findings also provide an evidence base for current guidelines, 6 which recommend that in OHS, supplemental oxygen should be titrated to maintain SpO 2 88-92%, thereby avoiding hyperoxia and hypoxaemia. Oxygen supplementation should also include close monitoring and periodic reassessment of ABGs. 6 
Limitations
In this study, we documented acute responses to breathing supplemental oxygen for 20 min. Based on the time course of PavCO 2 (figure 3), a plateau in PavCO 2 occurred after 10 min of breathing oxygen. However, due to the large capacity of the body for CO 2 storage, CO 2 equilibrium is not usually achieved until 20-30 min after a change in ventilation 33 and therefore participants may not have reached CO 2 steady state. In clinical practice, patients are usually treated with supplemental oxygen for extended periods. Hence, the effects of longer periods of supplemental oxygen require evaluation to further strengthen clinical practice guidelines.
CONCLUSION
Among people with mild, stable untreated OHS, breathing moderate concentrations of supplemental oxygen increased PavCO 2 , sufficient to induce acidaemia during F i O 2 0.50. These findings highlight the need for caution during supplemental oxygen administration among people with OHS and support current clinical guidelines which recommend targeting an SpO 2 range and monitoring of ABGs during supplemental oxygen administration.
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